Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.

被引：0
|
作者：
Sholler, Giselle Linda Saulnier
Ferguson, William
Bergendahl, Genevieve
Clinch, Thomas
Kraveka, Jacqueline M.
机构：
[1] Penn State Hlth Childrens Hosp, Hershey, PA USA
[2] St Louis Univ, St Louis, MO 63103 USA
[3] US WorldMeds, Louisville, KY USA
[4] Med Univ South Carolina, Charleston, SC 29425 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10060
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Local Control and Clinical Outcome of High-risk Pediatric Neuroblastoma Patients After Receiving Multimodality Treatment and Helical Tomotherapy
    Chen, Guann-Yiing
    Cheng, Jason Chia-Hsien
    Chen, Yu-Hsuan
    Lu, Meng-Yao
    Chang, Hsiu-Hao
    Yang, Yung-Li
    Jou, Shiann-Tarng
    Hsu, Wen-Ming
    Kuo, Sung-Hsin
    ANTICANCER RESEARCH, 2019, 39 (04) : 2207 - 2215
  • [32] Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    A J Jakubowiak
    D S Siegel
    T Martin
    M Wang
    R Vij
    S Lonial
    S Trudel
    V Kukreti
    N Bahlis
    M Alsina
    A Chanan-Khan
    F Buadi
    F J Reu
    G Somlo
    J Zonder
    K Song
    A K Stewart
    E Stadtmauer
    B L Harrison
    A F Wong
    R Z Orlowski
    S Jagannath
    Leukemia, 2013, 27 : 2351 - 2356
  • [33] Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
    Avet-Loiseau, Herve
    Bahlis, Nizar J.
    Chng, Wee-Joo
    Masszi, Tamas
    Viterbo, Luisa
    Pour, Ludek
    Ganly, Peter
    Palumbo, Antonio
    Cavo, Michele
    Langer, Christian
    Pluta, Andrzej
    Nagler, Arnon
    Kumar, Shaji
    Ben-Yehuda, Dina
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Berg, Deborah
    Lin, Jianchang
    van de Velde, Helgi
    Esseltine, Dixie-Lee
    di Bacco, Alessandra
    Moreau, Philippe
    Richardson, Paul G.
    BLOOD, 2017, 130 (24) : 2610 - 2618
  • [34] Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    Jakubowiak, A. J.
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Harrison, B. L.
    Wong, A. F.
    Orlowski, R. Z.
    Jagannath, S.
    LEUKEMIA, 2013, 27 (12) : 2351 - 2356
  • [35] A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas
    Svoboda, Jakub
    Strelec, Lauren
    Shah, Nirav Niranjan
    Chong, Elise A.
    Montrey, Kathleen
    Walsh, Kristy
    Huntington, Scott F.
    Mato, Anthony
    Landsburg, Daniel Jeffrey
    Nasta, Sunita
    Schuster, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Survival and palliative care decision making in high-risk neuroblastoma patients with refractory or relapsed disease: Experience from two paediatric oncology centres in the UK
    Ramanujachar, Ramya
    Marshall, Lynley
    Delany, Judith
    Brock, Penelope
    Pritchard-Jones, Kathy
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 568 - 568
  • [37] Temozolomide versus Irinotecan-Temozolomide for Children with Relapsed and or Refractory High-Risk Neuroblastoma (RR-HRNB). Results of the Beacon-Neuroblastoma Randomized Phase II Trial, an ITCC-SIOPEN Trial
    Moreno, L.
    Moroz, V.
    Owens, C.
    Valteau-Couanet, D.
    Gambart, M.
    van Eijkelenburg, N.
    Zwaan, C. M.
    Castel, V.
    Murphy, D.
    Morland, B.
    Gray, J.
    Marshall, L.
    Burchill, S.
    Chesler, L.
    Peet, A.
    Schleiermacher, G.
    Fenwick, N.
    Kearns, P.
    Pearson, A.
    Wheatley, K.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S34 - S34
  • [38] Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma
    Larrosa, Crstina
    Simao Rafael, Margarida
    Pablo Munoz, Juan
    Gorostegui, Maite
    Castaneda Heredia, Alicia
    Garraus, Moira
    Mora, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.
    Wheatley, Keith
    Holt, Grace
    Owens, Cormac
    Laidler, Jennifer
    Valteau-Couanet, Dominique
    Gambart, Marion
    Castel, Victoria
    van Eijkelenburg, Natasha
    Castellano, Aurora
    Nysom, Karsten
    Gerber, Nicolas U.
    Laureys, Genevieve
    Ladenstein, Ruth Lydia
    Makin, Guy
    Vaidya, Sucheta
    Thebaud, Estelle
    Kearns, Pamela
    Pearson, Andrew D. J.
    Moreno, Lucas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Influence of Adjuvant Radiotherapy Timing on Survival Outcomes in High-Risk Patients Receiving Neoadjuvant Treatments
    Cao, Lu
    Xu, Cheng
    Wang, Meng-Di
    Qi, Wei-Xiang
    Cai, Gang
    Cai, Rong
    Wang, Shu-Bei
    Ou, Dan
    Li, Min
    Shen, Kun-Wei
    Chen, Jia-Yi
    FRONTIERS IN ONCOLOGY, 2022, 12
12345